Bloomberg has a nice piece documenting a number of instances in which drug companies have promoted their drugs for uses not approved by the Food and Drug Administration and it harmed or killed patients. The part missing from this discussion is any discussion of the perverse incentives that patent monopolies create for promoting off-label uses. This is a strong argument for using alternative methods for financing research. By contrast, the article indicates that we have to hope that: "that drug companies actually honor the promises they keep making."
Unlike many news organizations, the Prospect has remained staunchly committed to keeping our journalism free and accessible to all. We believe that independent journalism is crucial for a functioning democracy—but quality reporting comes at a cost. From Trump’s threat to the free press to Musk’s influence on our democracy, there is too much at stake in 2025 to stop now.
We’re behind on our goal to raise $75,000 to continue delivering the hard-hitting investigative journalism you’ve come to expect from us. Your support helps us maintain our independence and dig deeper into the stories that matter most.
We need you to make a year-end contribution today. Any amount helps secure our future and ensure we can continue holding power to account.
